Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD5 | P21918 | 1/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383244 | 1.00 | DRD2 (0.49) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL17327306 | 1.00 | DRD2 (0.49) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL2258306 | 0.90 | DRD2 (0.47) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL2258302 | 0.90 | DRD2 (0.47) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL16969287 | 0.90 | DRD3 (0.45) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL16762854 | 0.89 | DRD2 (0.49) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL5531169 | 0.89 | DRD2 (0.47) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL4334143 | 0.89 | DRD2 (0.49) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL2258441 | 0.88 | DRD2 (0.49) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL899642 | 0.88 | DRD2 (0.49) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10987322-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20170112785-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2017-04-27 | — | — | US | disclosed |
| EP-3151820-A1 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9321728-B2 | Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-04-26 | — | — | US | disclosed |
| US-9321728-B2 | Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-04-26 | — | — | US | disclosed |
| WO-2015188085-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| US-20150329504-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-11-19 | — | — | US | disclosed |
| US-20150329504-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-11-19 | — | — | US | disclosed |
| EP-2842938-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2015-03-04 | — | — | EP | disclosed |
| EP-2842938-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2015-03-04 | — | — | EP | disclosed |
| WO-2012112364-A1 | LACTAM DERIVATIVES AS DGAT-1 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012044567-A2 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| EP-2408744-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010107768-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100197590-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC | 2010-08-05 | — | — | US | disclosed |
| US-20070244096-A1 | Fused Bicyclic Nitrogen-Containing Heterocycles | JAPAN TOBACCO INC. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244096-A1 | Fused Bicyclic Nitrogen-Containing Heterocycles | JAPAN TOBACCO INC. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-7244727-B2 | Fused bicyclic nitrogen-containing heterocycles | JAPAN TOBACCO INC. (JP) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329504-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | DGAT1, GOT1, ACAT2 | DRD2 4250/4885DRD3 3962/4885DRD1 3014/4885 |
| US-20100197590-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | CYP3A7, QDPR, DHFR | DRD2 165/4885DRD3 140/4885DRD1 139/4885 |
| US-20170112785-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | DRD2 2086/4885DRD3 2070/4885DRD1 2796/4885 |
| US-10987322-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | DRD2 2086/4885DRD3 2070/4885DRD1 2796/4885 |
| US-20070244096-A1 | Fused Bicyclic Nitrogen-Containing Heterocycles | PC, HCCS, MYC | DRD2 4707/4885DRD3 4646/4885DRD1 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.